{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:50:07Z","timestamp":1792093807202,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.scib.2026.07.061","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:31:39Z","timestamp":1784820699000},"page":"5012-5025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-confined nano-activators for antigen-independent broad activation of tumor-infiltrating T cells"],"prefix":"10.1016","volume":"71","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Tang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Qun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Zhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Dang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2026.07.061_b0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2026.07.061_b0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0015","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/d41586-024-00841-y","article-title":"How does a cancer vaccine work?","volume":"627","author":"Drew","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.07.061_b0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2026.07.061_b0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.07.061_b0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41565-023-01498-w","article-title":"Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours","volume":"19","author":"Wang","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.scib.2026.07.061_b0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.07.061_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd3220","article-title":"Sipuleucel-T","volume":"9","author":"Higano","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.07.061_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.scib.2026.07.061_b0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.scib.2026.07.061_b0065","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/D3CS00162H","article-title":"Advancing nanotechnology for neoantigen-based cancer theranostics","volume":"53","author":"Zou","year":"2024","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.scib.2026.07.061_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/science.adu7686","article-title":"Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors","volume":"391","author":"Wang","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.scib.2026.07.061_b0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/toxins14110800","article-title":"Superantigens, a paradox of the immune response","volume":"14","author":"Noli Truant","year":"2022","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.scib.2026.07.061_b0080","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115987119","article-title":"Superantigens promote Staphylococcus aureus bloodstream infection by eliciting pathogenic interferon-\u03b3 production","volume":"119","author":"Tuffs","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.scib.2026.07.061_b0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.smim.2007.04.006","article-title":"TCR recognition of peptide\/MHC class II complexes and superantigens","volume":"19","author":"Sundberg","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1016\/j.scib.2026.07.061_b0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41577-023-00979-2","article-title":"Novel insights into the immune response to bacterial T cell superantigens","volume":"24","author":"Tuffs","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.scib.2026.07.061_b0095","article-title":"High-affinity superantigen-based trifunctional immune cell engager synergizes NK and T cell activation for tumor suppression","volume":"11","author":"Yu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.scib.2026.07.061_b0100","article-title":"Continuous oral administration of the superantigen staphylococcal enterotoxin C2 activates intestinal immunity and modulates the gut microbiota in mice","volume":"11","author":"Gu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.scib.2026.07.061_b0105","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.apsb.2025.03.019","article-title":"Submicron-sized superantigen biomimetic liposomes with highly efficient pulmonary accumulation to remodel local immune microenvironment for cancer chemoimmunotherapy","volume":"15","author":"Yuan","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.scib.2026.07.061_b0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/toxins11030178","article-title":"Staphylococcal superantigens: pyrogenic toxins induce toxic shock","volume":"11","author":"Krakauer","year":"2019","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.scib.2026.07.061_b0115","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2008.20.2515","article-title":"Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer","volume":"27","author":"Borghaei","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0120","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-15-0580","article-title":"A randomized phase II\/III study of Naptumomab Estafenatox + IFN\u03b1 vs. IFN\u03b1 in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis","volume":"22","author":"Hawkins","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.scib.2026.07.061_b0125","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.scib.2026.07.061_b0130","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41590-025-02308-2","article-title":"Cancer vaccines as enablers of immunotherapy","volume":"26","author":"Khleif","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2026.07.061_b0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0140","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41467-023-37656-w","article-title":"Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2026.07.061_b0145","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/15548627.2025.2608974","article-title":"Measuring lysosome damage and lysophagy in vivo","volume":"22","author":"Wu","year":"2026","journal-title":"Autophagy"},{"key":"10.1016\/j.scib.2026.07.061_b0150","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","article-title":"PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function","volume":"629","author":"Morotti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.scib.2026.07.061_b0155","article-title":"Long\u2010term storage stable vesicle\u2010like nanoparticles of lipid and polymer for siRNA and mRNA\u2010mediated cancer immunotherapy","volume":"34","author":"Chen","year":"2024","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.scib.2026.07.061_b0160","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.4049\/jimmunol.1400980","article-title":"Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome","volume":"193","author":"Tilahun","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.scib.2026.07.061_b0165","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2026.07.061_b0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41590-023-01733-5","article-title":"Metabolic waypoints during T cell differentiation","volume":"25","author":"Wilfahrt","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2026.07.061_b0175","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.2022017795","article-title":"Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.scib.2026.07.061_b0180","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","article-title":"Bystander IFN-\u03b3 activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment","volume":"1","author":"Thibaut","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.scib.2026.07.061_b0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.gt.3302280","article-title":"Tumor-specific gene expression using the survivin promoter is further increased by hypoxia","volume":"11","author":"Yang","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.scib.2026.07.061_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-4598-10-35","article-title":"Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin","volume":"10","author":"Kelly","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1016\/j.scib.2026.07.061_b0195","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.scib.2026.07.061_b0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2013BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.scib.2026.07.061_b0210","doi-asserted-by":"crossref","DOI":"10.1007\/s11431-025-3099-1","article-title":"In vivo CAR-T cell therapy and its technologies: a perspective","volume":"68","author":"Zhou","year":"2025","journal-title":"Sci China Technol Sci"},{"key":"10.1016\/j.scib.2026.07.061_b0215","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome","volume":"143","author":"Vadivel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.scib.2026.07.061_b0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.scib.2026.07.061_b0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209592732600842X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209592732600842X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:30:43Z","timestamp":1792092643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209592732600842X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S209592732600842X"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2026.07.061","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-confined nano-activators for antigen-independent broad activation of tumor-infiltrating T cells","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2026.07.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Science China Press. Published by Elsevier B.V. and Science China Press. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}